home / stock / bixt / bixt quote
Last: | $0.12 |
---|---|
Change Percent: | 0.0% |
Open: | $0.12 |
Close: | $0.12 |
High: | $0.12 |
Low: | $0.1101 |
Volume: | 6,459 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.12 | $0.12 | $0.12 | $0.12 | $0.1101 | 6,459 | 07-26-2024 |
$0.12 | $0.115 | $0.12 | $0.12 | $0.112575 | 11,401 | 07-25-2024 |
$0.125 | $0.119 | $0.125 | $0.125 | $0.1186 | 11,001 | 07-24-2024 |
$0.125 | $0.1199 | $0.125 | $0.129 | $0.1199 | 31,002 | 07-23-2024 |
$0.124 | $0.129 | $0.124 | $0.129 | $0.124 | 3,432 | 07-22-2024 |
$0.11805 | $0.11805 | $0.11805 | $0.11805 | $0.11805 | 1,000 | 07-19-2024 |
$0.125 | $0.11505 | $0.125 | $0.125 | $0.1075 | 51,498 | 07-18-2024 |
$0.12 | $0.099 | $0.12 | $0.12 | $0.0891 | 682,961 | 07-17-2024 |
$0.089 | $0.083 | $0.089 | $0.089 | $0.083 | 30,404 | 07-16-2024 |
$0.0846 | $0.081 | $0.0846 | $0.089 | $0.081 | 5,974 | 07-15-2024 |
$0.0865 | $0.089 | $0.0865 | $0.089 | $0.0865 | 380 | 07-12-2024 |
$0.085 | $0.09495 | $0.085 | $0.09495 | $0.0805 | 77,394 | 07-11-2024 |
$0.09495 | $0.091 | $0.09495 | $0.09495 | $0.091 | 5,583 | 07-10-2024 |
$0.091 | $0.0902 | $0.091 | $0.09495 | $0.0902 | 30,084 | 07-09-2024 |
$0.0902 | $0.091 | $0.0902 | $0.092 | $0.0865 | 507,994 | 07-08-2024 |
$0.087 | $0.098 | $0.087 | $0.098 | $0.087 | 1,006 | 07-05-2024 |
$0.092 | $0.0803 | $0.092 | $0.092 | $0.0803 | 151,100 | 07-04-2024 |
$0.092 | $0.0803 | $0.092 | $0.092 | $0.0803 | 151,100 | 07-03-2024 |
$0.0839 | $0.08515 | $0.0839 | $0.0872 | $0.0803 | 108,817 | 07-02-2024 |
$0.0975 | $0.0975 | $0.0975 | $0.0975 | $0.0975 | 33,768 | 07-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
The Heme Foundation and Bioxytran join forces to address the global blood supply shortage BOSTON, MASSACHUSETTS, July 18, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to t...
BXT-25 is expected to oxygenate the brain BOSTON, MASSACHUSETTS, June 27, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer's disease, announced that Bioxtran’s...
X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...